#United States #New York #Class Action #Levi & Korsinsky #Capricor Therapeutics

Levi & Korsinsky Notifies Investors of Class Action Lawsuit Against Capricor Therapeutics

Overview

Levi & Korsinsky, LLP has announced a class action lawsuit involving investors of Capricor Therapeutics, Inc. This case pertains to potential securities fraud that occurred between October 9, 2024, and July 10, 2025. Investors who believe they have been impacted are encouraged to take action as there is an approaching deadline for becoming a lead plaintiff in the lawsuit.

Class Action Definition

The class action aims to recover losses suffered by investors who were misled by Capricor due to misleading statements regarding their lead cell therapy candidate, deramiocel, which was intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The lawsuit highlights how the defendants allegedly provided investors with optimistic information while concealing critical adverse facts about the safety and efficacy of the drug as reported in the Phase 2 HOPE-2 trial study.

Case Details

In the official complaint, it is noted that the defendants claimed Capricor was on track to obtain a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). Unfortunately, on July 11, 2025, Capricor announced that it had received a Complete Response Letter (CRL) from the FDA, which denied the BLA, citing inadequacies in evidence of effectiveness as well as necessary additional clinical data. Following this news, the stock price of Capricor dropped significantly from $11.40 per share to $7.64 per share in a single day, impacting many investors adversely.

Next Steps for Investors

Investors who experience losses during the period from October 9, 2024, to July 10, 2025, must act by the deadline of September 15, 2025, if they hope to be appointed as lead plaintiffs. However, it is important to note that potential recoveries do not require becoming a lead plaintiff.

No Cost Involved

For those who are part of the class action, there are no out-of-pocket costs or fees involved. Participation is free, and there is no obligation to continue.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has a strong reputation earned over 20 years, having secured hundreds of millions of dollars for shareholders and maintaining a successful track record in high-stakes securities litigation. With a dedicated team of over 70 professionals, the firm has been recognized as one of the top litigation firms in the United States by ISS Securities Class Action Services for seven consecutive years.

Contact Information

For additional information, affected investors can contact Joseph E. Levi, Esq., at Levi & Korsinsky, LLP. The firm’s contact details are as follows:

• - Email: [email protected]
• - Phone: (212) 363-7500
• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

For those interested in following up, interested investors can click on the provided link to gain further insights and possibly be contacted by a member of the legal team.

Conclusion

Informed investors should be aware of their rights and options regarding the ongoing Capricor Therapeutics class action. The developments in this case highlight the importance of transparency from companies regarding their operational challenges and regulatory compliance. As this situation unfolds, affected individuals should stay vigilant and consider their next steps carefully.